Background: Thirty-one Russian patients with late complement component deficiency (LCCD) who had experienced one to five meningococcal infections were immunized with meningococcal polysaccharide vaccine (A + C + W135 + Y) and were followed for 3–8 years. We investigated the potentially protective killing effect of human neutrophils (PMNL) on serogroup A and W135 meningococci. Methods: Meningococci were incubated in LCCD vaccinee sera in the absence or presence of PMNL, and the number of live bacteria (CFU) was determined by plating onto chocolate agar. Results: When meningococci were incubated in the LCCD sera alone, exponential growth of meningococci occurred despite the presence of meningococcal antibodies. After the addition of PMNL, meningococci were inhibited in their growth or even eliminated. Group A or W135 meningococci were killed effectively by PMNL in 80% of the sera which were collected 1 month to 1 year after vaccination compared to only 40% in the prevaccination LCCD sera (p < 0.05). Three years after vaccination 67% of the LCCD sera were still capable of promoting killing (and even 90% after revaccination). The rate of killing correlated with the concentration of serogroup-specific immunoglobulins. In 83% of the 72 LCCD sera with more than 5 µg/ml anti-group A immunoglobulins the killing of group A meningococci was promoted. By contrast, only 21% of 19 samples with lower specific antibody levels showed a PMNL-mediated meningococcal killing (p < 0.05). The same effect was observed for group W135 meningococci. Conclusion: PMNL kill meningococci during incubation in LCCD serum; this effect increases after vaccination and depends on both specific antibody and complement. Protection by vaccination may therefore be caused by an increased killing capacity of PMNL.

1.
Figueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991;4:359–395.
2.
Fredlund H: Serum factors and polymorphonuclear leukocytes in human host defense against Neisseria meningitidis: Studies with special reference to a chemiluminometric technique. Scand J Infect Dis 1993(suppl S7):1–72.
3.
Griffiss JM: Mechanism of host immunity; in Cartwright K (ed): Meningococcal Disease. Chichester, Wiley, 1995, pp 35–70.
4.
Peltola H: Meningococcal vaccines. Current status and future possibilities. Drugs 1998;55:347–366.
5.
Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, Raff HV: A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5:479–485.
6.
Platonov AE, Beloborodov VB, Vershinina IV: Meningococcal disease in patients with late complement components deficiency: Studies in the USSR. Medicine (Baltimore) 1993;72:374–392.
7.
Platonov AE, Kuijper EJ, Vershinina IV, Shipulin GA, Westerdaal N, Fijen CAP, van de Winkel JGJ: Meningococcal disease and polymorphism of FcγRIIa receptors (CD32) in late complement component individuals. Clin Exp Immunol 1998;111:97–101.
8.
Platonov AE, Shipulin GA, Vershinina IV, Dankert J, van de Winkel JCJ, Kuijper EJ: Association of human FcγRII (CD32) polymorphism with susceptibility to and severity of meningococcal disease. Clin Infect Dis 1998;27:746–750.
9.
Ross SC, Rosenthal PJ, Berberich HM, Densen P: Killing of Neisseria meningitidis by human neutrophils: Implication for normal and complement-deficient individuals. J Infect Dis 1987;155:1266–1275.
10.
Söderström C, Braconier JH, Sjöholm AG, Thuresson B: Granulocte functions and Neisseria meningitidis: Influence of properdin-deficient serum. APMIS 1991;99:965–971.
11.
Andreoni J, Käyhty H, Densen P: Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals. J Infect Dis 1993;168:227–231.
12.
Schlesinger M, Greenberg R, Levy J, Käyhty H, Levy R: Killing of meningococci by neutrophils: Effect of vaccination on patients with complement deficiency. J Infect Dis 1994;170:449–453.
13.
Estabrook MM, Christopher NC, Griffiss JM, Baker CJ, Mandrell RE: Sialyation and human neutrophil killing of group Neisseria meningitidis. J Infect Dis 1992;166:1079–1088.
14.
Maslanksa SE, Gheesling LL, LiButti DE, et al: Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997;4:156–167.
15.
Platonov AE, Beloborodov VB, Pavlova LI, Vershinina IV, Käyhty H: Vaccination of patients deficient in a late complement component with tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1995;100:32–39.
16.
Fijen CA, Kuijper EJ, Drogari-Apiranthitou M, Van Leeuwen Y, Daha MR, Dankert J: Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine. Clin Exp Immunol 1998;114:362–369.
17.
Platonov AE, Vershinina IV, Dankert J, Kuijper EJ, Gustafson L, Käyhty H: Long-term follow-up of late complement component deficient patients vaccinated with meningococcal polysaccharide vaccine: Antibody persistence and efficacy of vaccination; in Zollinger WD, Frasch CE, Deal CD (eds): Pathogenic Neisseria. Baltimore, Tenth International Pathogenic Neisseria Conference, 1996, pp 235–236.
18.
Platonov AE, Beloborodov VB, Gabrilovitch DI, Khabarov VV, Serebrovskaya LV: Immunological evaluation of late complement component-deficient individuals. Clin Immunol Immunopathol 1992;64:98–105.
19.
Koroleva IS, Platonov AE, van der Ende A, Kuijper EJ, Dankert J: Characteristics of pathogenic Neisseria meningitidis in Moscow: Prevalence of ‘non-European’ strains. Clin Microbiol Infect 1998;4:123–128.
20.
Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA: An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990;135:121–128.
21.
Holder PK, Maslanksa SE, Pais LB, Dykes J, Plikaytis BD, Carlone GM: Assignment of Neisseria meningitidis serogroup A and C class-specific anticapsular antibody concentrations to the new standard reference serum CDC 1992. Clin Diagn Lab Immunol 1995;2:132–137.
22.
Barclay GR: Endogenous endotoxin-core antibody (EndoCAb) as a marker of endotoxin exposure and a prognostic indicator: A review; in Levin J, Alving CR, Munford RS, Redl H (eds): Bacterial Endotoxin: Lipopolysaccharides from Genes to Therapy. New York, Wiley-Liss, 1995, pp 263–272.
23.
Arduino RC, Murray BE, Rakita RM: Roles of antibodies and complement in phagocytic killing of enterococci. Infect Immun 1994;62:987–993.
24.
Vershinina IV, Platonov AE: Do complainants eat components? Do components eat complainants? Kinetic aspects of the interaction of complement system and meningococci; in Nassif X, Quentin-Millet M-J, Taha M-K (eds): Abstracts of the 11th International Pathogenic Neisseria Conference. Paris, Editions EDK 1998, p 77.
25.
Noah N, Henderson B: Surveillance of Bacterial Meningitis in Europe 1999/2000. London, PHLS, 2001.
26.
Fijen CAP: Meningococcal Disease and Complement Deficiencies in the Netherlands; thesis University of Amsterdam, 1995.
27.
Lehmann AK, Sørnes S, Halstensen A: Phagocytosis: Measurement by flow cytometry. J Immunol Methods 2000;243:229–242.
28.
McNeil G, Virji M, Moxon ER: Interaction of Neisseria meningitidis with human monocytes. Microb Pathog 1994;16:153–163.
29.
Densen P, Mandell GL: Granuloyte phagocytes; in Mandell GL, Douglas RG Jr, Bennett JE (eds): Principles and Practice of Infectious Diseases. New York, Churchill Livingstone, 1990, pp 81–101.
30.
Levy O: Antibiotic proteins of polymorphonuclear leukocytes. Eur J Haematol 1996;56:263–277.
31.
Selsted ME, Quelette AJ: Defensins in granules of phagocytic and non-phagocytic cells. Trends Cell Biol 1995;5:114–119.
32.
Brandtzaeg P: Pathogenesis of meningococcal infection; in Cartwright K (ed): Meningococcal Disease. Chichester, Wiley, 1995, pp 71–114.
33.
Drogari-Apiranthitou M, Fijen CAP, van de Beek D, Hensen EF, Dankert J, Kuijper EJ: Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients. Clin Exp Immunol 2000;119:311–316.
34.
Jones SL, Brown EJ: Functional cooperation between Fcγ receptors and complement receptors in phagocytes; in van de Winkel JCJ, Capel PJA (eds): Human IgG Fc Receptors. Austin, RG Landes, 1996, pp 148–163.
35.
Morgan BP, Orren A: Vaccination against meningococcus in complement-deficient individuals. Clin Exp Immunol 1998;114:327–329.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.